We make entering the US healthcare market easy, efficient, and impactful.
Commercial clarity so you can navigate the complex US healthcare landscape to get to revenue and validation quicker.
US commercialization is where you win.
It’s also where the risk is.
The sales cycle is long, winding, and opaque: 6-18 months; filled with numerous stakeholders, some of whom have conflicting priorities; and packed with a maze of budget structures and a marathon of procurement processes.
Navigating Regulatory and Reimbursement just gets you a ticket into the game. It doesn’t teach you the rules to the game or train you with the skills to play competitively.
And it certainly doesn’t illuminate how you’ll win.
The US healthcare market is demanding, complex, and highly competitive.
Different isn’t enough. Clinical validation isn’t enough. Interesting isn’t enough.
Technologies—especially novel ones—must be supported by a business. The companies who succeed in the US engrain new technologies in businesses that make sense for care delivery facilities to smoothly adopt.
The challenge of forging ahead without incorporating the impact on revenue, workflow, and patient outcomes of a new technology is akin to entering the Tour de France with a top tier bicycle with the wrong tires, no experience in a race with these specific rules, and no map of the course—the gears may be brilliant and the rider dedicated, but winning is unlikely.
The bicycle may currently be modified to be incongruent with the race at hand, and the various values may not be useful with the rules of this race.
Understanding how to adapt to win, and what revenue, workflow, and clinical cases are structured to align with your use case, is mission-critical.
Yet international healthtech companies can absolutely succeed in the US.
Commercial success in the US for an international company takes a different approach, with different requirements, than the traditional domestic pathways.
Many organizations assume international companies ought to simply understand the US healthcare systems, adapt, and proceed according to the same commercial process as domestic companies–but this is shortsighted.
Retrofitting domestic strategy to suit international companies simply costs them time, money, and frustration.
International companies have a different set of tools at their disposal than their domestic counterparts at the same stage. It’s critical to work with specialists who understand this very specific intersection of commercial development and investment from an international perspective.
The international advantage
We believe that our international collaborations with entrepreneurs, researchers, and leading institutions benefit everyone–and that these partnerships can be truly mutually beneficial.
Internationally scaling companies tend to have lower clinical and technical risk, a tremendous fortitude for navigating bureaucracies, and patient- and provider-centric perspectives that contribute to the Quadruple Aim.
What remains is commercial navigation, adapting models from Bismark and Beveridge and everything in between, and phasing entry in a strategic manner that makes sense for tranched funding.
Given traditional differences in valuation, this means that US investors find lower-risk companies for the same check size–as long as they have a grounded market entry strategy and the right partners in place to execute.
Get current, real-world resources & insights
01. Apply to join the Healthtech Bridge program
12-week commercial course designed specifically for international healthtech scaleups, get to US revenue and validation faster and more efficiently.
03. Deal scouting & market access pulse
Full portfolio support—from deal scouting on the US investment side to providing insights and opportunities to EU investors
02. Actual, actionable answers
Sometimes you just need real-world insights, clarity, and some straightforward advice on an upcoming decision—and it just can’t wait.
04. Pre-order “Flight Rules”
Get the book that shares how to keep your scaleup under control and flying in turbulent times. Written by veteran commercial leaders.
Contact us
Venture Atlas labs© 2024 | All rights reserved | Privacy Policy